Gurusamy Kurinchi S, Imber Charles, Davidson Brian R
University Department of Surgery, UCL and Royal Free Hospital NHS Trust, Royal Free and University College School of Medicine, London NW3 2QG, UK.
HPB Surg. 2008;2008:684150. doi: 10.1155/2008/684150.
Hepatic lymph node involvement is generally considered a contraindication for liver resection performed for colorectal liver metastases. However, some advocate hepatic lymphadenectomy in the presence of macroscopic involvement and others routine lymphadenectomy. The aim of this review is to assess the role of lymphadenectomy in resection of liver metastases from colorectal cancer.
Medline, Embase and Central databases were searched using a formal search strategy. Trials with survival data with a minimum follow-up of 1 year were considered for inclusion. Meta-analysis was performed using Revman.
A total of 4230 references were identified. Ten reports of nine studies including 926 patients qualified for the review. The prevalence of nodal metastases after routine lymphadenectomy was 16.3%. The overall 3-year and 5-year survival rates in node-positive patients were 9/151 (11.3%) and 2/137 (1.5%), respectively, compared to 3-year and 5-year survival rates of 424/787 (53.9%) and 246/767 (32.1%) in node-negative patients. The odds ratios for 3-year and 5-year survivals in node positive disease compared to node-negative disease were 0.12 (95% CI 0.06 to 0.24) and 0.08 (95% CI 0.03 to 0.22). There was no randomized controlled trial which assessed the survival benefit of routine or "selective" lymphadenectomy.
Currently, there is no evidence of survival benefit for routine or selective lymphadenectomy. Survival rates are low in patients with positive lymph nodes draining the liver irrespective of whether they are detected by routine lymphadenectomy or by macroscopic involvement. Further trials in this patient group are required.
肝淋巴结受累通常被视为结直肠癌肝转移行肝切除的禁忌证。然而,一些人主张在存在肉眼可见受累时行肝淋巴结清扫术,另一些人则主张常规淋巴结清扫术。本综述的目的是评估淋巴结清扫术在结直肠癌肝转移切除中的作用。
使用正式检索策略对Medline、Embase和Central数据库进行检索。纳入至少随访1年的有生存数据的试验。使用Revman进行荟萃分析。
共识别出4230篇参考文献。9项研究的10篇报告包括926例符合综述条件的患者。常规淋巴结清扫术后淋巴结转移的发生率为16.3%。淋巴结阳性患者的3年和5年总生存率分别为9/151(11.3%)和2/137(1.5%),而淋巴结阴性患者的3年和5年生存率分别为424/787(53.9%)和246/767(32.1%)。与淋巴结阴性疾病相比,淋巴结阳性疾病3年和5年生存的优势比分别为0.12(95%CI 0.06至0.24)和0.08(95%CI 0.03至0.22)。没有随机对照试验评估常规或“选择性”淋巴结清扫术的生存获益。
目前,没有证据表明常规或选择性淋巴结清扫术能带来生存获益。无论肝引流区淋巴结阳性是通过常规淋巴结清扫术还是肉眼可见受累发现,患者生存率都很低。该患者群体需要进一步的试验。